Although maybe the incidence of infections in the 12-week VRTX trial is some preliminary support for INCY's theory.
Tofacitinib hits JAK3, it works out fine. It would be interesting to see how VRTX's infection rate breaks along dosage - from abstract it seems it is dose related. VRTX is going to evaluate more dose regimen (qd, bid) in combination with methotrexate in ph2b.
Market Data 
Markets 
AI
